A PHASE 2 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY EFFICACY STUDY OF SITAXSENTAN SODIUM TO IMPROVE IMPAIRED EXERCISE TOLERANCE IN SUBJECTS WITH DIASTOLIC HEART FAILURE
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Sitaxentan (Primary)
- Indications Diastolic heart failure
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Jul 2011 Additional trial location (Canada) added as reported by ClinicalTrials.gov.
- 08 Apr 2009 Company Encysive Pharmaceuticals change to Pfizer as trial sponsor/affiliate, Addition of trial centre as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.